{"id":3535,"date":"2018-05-03T11:01:25","date_gmt":"2018-05-03T10:01:25","guid":{"rendered":"https:\/\/colox.ch\/?post_type=avada_faq&#038;p=3535"},"modified":"2018-05-03T11:01:25","modified_gmt":"2018-05-03T10:01:25","slug":"performances-et-avantages-du-test-colox","status":"publish","type":"avada_faq","link":"https:\/\/colox.ch\/fr\/faq-items\/performances-et-avantages-du-test-colox\/","title":{"rendered":"Performances et Avantages du test Colox\u00ae"},"content":{"rendered":"<p><strong><span style=\"color: #ff6600;\">&gt;<\/span> Colox\u00ae est-il fiable ?<br \/>\n<\/strong>Les performances du test ont \u00e9t\u00e9 valid\u00e9es lors d\u2019une \u00e9tude clinique multicentrique de type cas-contr\u00f4le men\u00e9e en Suisse, incluant 782 individus. Il a d\u00e9tect\u00e9 78 % des patients souffrant d\u2019un cancer du c\u00f4lon et 52 % des patients pr\u00e9sentant des polypes ad\u00e9nomateux. La sensibilit\u00e9 du test pour la d\u00e9tection de stade pr\u00e9coce est de 61%. La sp\u00e9cificit\u00e9 du test est de 92,2% c\u2019est-\u00e0-dire moins d\u2019une personne sur 10 a \u00e9t\u00e9 test\u00e9e positive alors qu\u2019elle ne pr\u00e9sentait pas de cancer du c\u00f4lon ni de polypes ad\u00e9nomateux. .<\/p>\n<p>A l\u2019heure actuelle 400 m\u00e9decins ont d\u00e9j\u00e0 prescrit Colox \u00e0 plus de 3000 patients.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><span style=\"color: #ff6600;\">&gt;<\/span> Quels sont les avantages du test Colox\u00ae ?<br \/>\n<\/strong>Le test Colox est un test simple puisqu\u2019il ne n\u00e9cessite qu\u2019une prise de sang par rapport \u00e0 certains tests plus invasifs et inconv\u00e9nients, n\u00e9cessitant une pr\u00e9paration des intestins ou bien une manipulation des selles. De plus, il ne requiert pas non plus d\u2019hospitalisation. Des \u00e9tudes cliniques ont prouv\u00e9 la performance du test Colox pour la d\u00e9tection efficace de cancers colorectaux. Enfin, Colox a de bonnes performances pour la d\u00e9tection des polypes ad\u00e9nomateux de plus de 1cm.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><span style=\"color: #ff6600;\">&gt;<\/span> Pourquoi un test sanguin ?<br \/>\n<\/strong>En Suisse, seulement 10% de la population cible acceptent se r\u00e9aliser une coloscopie et 20% r\u00e9alisent des tests de recherche de sang dans les selles. Cela signifie que 70% de la population ne sont pas test\u00e9s. Un test sanguin a le potentiel d&rsquo;augmenter la participation au d\u00e9pistage dans la population admissible qui n&rsquo;est actuellement pas d\u00e9pist\u00e9e. Ce test est donc conseill\u00e9 pour les femmes et les hommes qui pr\u00e9f\u00e8rent la commodit\u00e9 d\u2019un test sanguin au test des selles ou qui pr\u00e9f\u00e8rent la simplicit\u00e9 d\u2019un test sanguin \u00e0 la proc\u00e9dure invasive d\u2019une coloscopie de d\u00e9pistage.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&gt; Colox\u00ae est-il fiable ? Les performances du test ont \u00e9t\u00e9 valid\u00e9es lors d\u2019une \u00e9tude clinique multicentrique de type cas-contr\u00f4le men\u00e9e en Suisse, incluant 782 individus. Il a d\u00e9tect\u00e9 78 % des patients souffrant d\u2019un cancer du c\u00f4lon et 52 % des patients pr\u00e9sentant des polypes ad\u00e9nomateux. La sensibilit\u00e9 du test pour la d\u00e9tection de [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","format":"standard","meta":{"footnotes":""},"faq_category":[65],"class_list":["post-3535","avada_faq","type-avada_faq","status-publish","format-standard","hentry","faq_category-professionnels-de-la-sante"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Performances et Avantages du test Colox\u00ae - Colox<\/title>\n<meta name=\"description\" content=\"Les performances du test ont \u00e9t\u00e9 valid\u00e9es lors d\u2019une \u00e9tude clinique multicentrique de type cas-contr\u00f4le men\u00e9e en Suisse, incluant 782 individus. Il a d\u00e9tect\u00e9 78 % des patients souffrant d\u2019un cancer du c\u00f4lon et 52 % des patients pr\u00e9sentant des polypes ad\u00e9nomateux.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Performances et Avantages du test Colox\u00ae - Colox\" \/>\n<meta property=\"og:description\" content=\"Les performances du test ont \u00e9t\u00e9 valid\u00e9es lors d\u2019une \u00e9tude clinique multicentrique de type cas-contr\u00f4le men\u00e9e en Suisse, incluant 782 individus. Il a d\u00e9tect\u00e9 78 % des patients souffrant d\u2019un cancer du c\u00f4lon et 52 % des patients pr\u00e9sentant des polypes ad\u00e9nomateux.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/\" \/>\n<meta property=\"og:site_name\" content=\"Colox\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/\",\"url\":\"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/\",\"name\":\"Performances et Avantages du test Colox\u00ae - Colox\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/de\/#website\"},\"datePublished\":\"2018-05-03T10:01:25+00:00\",\"dateModified\":\"2018-05-03T10:01:25+00:00\",\"description\":\"Les performances du test ont \u00e9t\u00e9 valid\u00e9es lors d\u2019une \u00e9tude clinique multicentrique de type cas-contr\u00f4le men\u00e9e en Suisse, incluant 782 individus. Il a d\u00e9tect\u00e9 78 % des patients souffrant d\u2019un cancer du c\u00f4lon et 52 % des patients pr\u00e9sentant des polypes ad\u00e9nomateux.\",\"breadcrumb\":{\"@id\":\"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/colox.ch\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FAQs\",\"item\":\"https:\/\/colox.ch\/avada_faq\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Performances et Avantages du test Colox\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/colox.ch\/de\/#website\",\"url\":\"https:\/\/colox.ch\/de\/\",\"name\":\"Colox\",\"description\":\"The new generation blood test\",\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/colox.ch\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/colox.ch\/de\/#organization\",\"name\":\"Novigenix SA\",\"url\":\"https:\/\/colox.ch\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"contentUrl\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"width\":700,\"height\":297,\"caption\":\"Novigenix SA\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Performances et Avantages du test Colox\u00ae - Colox","description":"Les performances du test ont \u00e9t\u00e9 valid\u00e9es lors d\u2019une \u00e9tude clinique multicentrique de type cas-contr\u00f4le men\u00e9e en Suisse, incluant 782 individus. Il a d\u00e9tect\u00e9 78 % des patients souffrant d\u2019un cancer du c\u00f4lon et 52 % des patients pr\u00e9sentant des polypes ad\u00e9nomateux.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/","og_locale":"fr_FR","og_type":"article","og_title":"Performances et Avantages du test Colox\u00ae - Colox","og_description":"Les performances du test ont \u00e9t\u00e9 valid\u00e9es lors d\u2019une \u00e9tude clinique multicentrique de type cas-contr\u00f4le men\u00e9e en Suisse, incluant 782 individus. Il a d\u00e9tect\u00e9 78 % des patients souffrant d\u2019un cancer du c\u00f4lon et 52 % des patients pr\u00e9sentant des polypes ad\u00e9nomateux.","og_url":"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/","og_site_name":"Colox","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/","url":"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/","name":"Performances et Avantages du test Colox\u00ae - Colox","isPartOf":{"@id":"https:\/\/colox.ch\/de\/#website"},"datePublished":"2018-05-03T10:01:25+00:00","dateModified":"2018-05-03T10:01:25+00:00","description":"Les performances du test ont \u00e9t\u00e9 valid\u00e9es lors d\u2019une \u00e9tude clinique multicentrique de type cas-contr\u00f4le men\u00e9e en Suisse, incluant 782 individus. Il a d\u00e9tect\u00e9 78 % des patients souffrant d\u2019un cancer du c\u00f4lon et 52 % des patients pr\u00e9sentant des polypes ad\u00e9nomateux.","breadcrumb":{"@id":"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/colox.ch\/fr\/avada_faq\/performances-et-avantages-du-test-colox\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/colox.ch\/"},{"@type":"ListItem","position":2,"name":"FAQs","item":"https:\/\/colox.ch\/avada_faq\/"},{"@type":"ListItem","position":3,"name":"Performances et Avantages du test Colox\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/colox.ch\/de\/#website","url":"https:\/\/colox.ch\/de\/","name":"Colox","description":"The new generation blood test","publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/colox.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/colox.ch\/de\/#organization","name":"Novigenix SA","url":"https:\/\/colox.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/","url":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","contentUrl":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","width":700,"height":297,"caption":"Novigenix SA"},"image":{"@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/avada_faq\/3535"}],"collection":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/avada_faq"}],"about":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/types\/avada_faq"}],"author":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/comments?post=3535"}],"version-history":[{"count":0,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/avada_faq\/3535\/revisions"}],"wp:attachment":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/media?parent=3535"}],"wp:term":[{"taxonomy":"faq_category","embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/faq_category?post=3535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}